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Background: The relationship between bacterial etiology and serum cytokine levels in patients with severe
community-acquired pneumonia (CAP) without response to initial empiric treatment remains unclear. This
study investigated the bacterial etiology, outcomes, and bronchoalveolar and systemic cytokines (interleukin
[IL]-1`, IL-8, IL-10) in these patients.
Methods: This hospital-based study enrolled 47 consecutive patients without response to initial empiric
treatment and requiring mechanical ventilation due to severe CAP between July 1, 2000 and October 31,
2001, in a respiratory intensive care unit of a 1200-bed teaching hospital in central Taiwan. Bronchoalveolar
lavage (BAL) was performed within 3 days after hospitalization. BAL fluid was processed for quantitative
bacterial cultures. Blood samples were taken just before BAL, and the levels of both BAL and serum cytokines
were measured.
Results: The most common pathogens isolated were Pseudomonas aeruginosa (22.5%) and Klebsiella pneumoniae
(25%). Patients with a K. pneumoniae isolate (n = 10) had significantly higher levels of IL-1` in BAL fluid
and significantly higher levels of IL-10 in serum and BAL fluid than patients with other etiologies. Non-
survivors had higher levels of serum IL-8 (p = 0.001), serum IL-10 (p < 0.001) and BAL IL-10 (p = 0.039) than
survivors. Marked increases in local and systemic cytokine expression (IL-8 and IL-10) were noted in rapidly
fatal cases.
Conclusion: P. aeruginosa and K. pneumoniae are the most common causes of CAP requiring mechanical
ventilation in Taiwan. Cytokine patterns in the BAL fluid and serum of patients with severe CAP due to K.
pneumoniae showed significant elevations compared to other pathogens. Bronchoalveolar and systemic cytokine
levels (especially IL-10) predicted mortality. These findings suggest the need for a clinical trial to determine
how immunomodulating therapy might affect cytokine profiles and clinical outcome. [ J Formos Med Assoc
2006;105(1):49–55]
Key Words: bronchoalveolar lavage, interleukin-1`, interleukin-8, interleukin-10, pneumonia
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
1Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, 2National Yang-Ming University School
of Medicine, Taipei, 3Department of Life Sciences, National Chung Hsing University, 4School of Medical Technology and 5Institute of Medicine, Chung-
Shan Medical University, Taichung, Taiwan, R.O.C.
Received: February 24, 2005
Revised: March 28, 2005
Accepted: June 7, 2005
Pneumonia is the eighth leading cause of death in
Taiwan. A recent study from a medical center in
central Taiwan reported that 42% of community-
acquired pneumonia (CAP) cases were class VI
and V using Fine’s pneumonia severity index.1
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Acute respiratory failure developed after initial
empiric therapy in 30% of cases. The association
between bacterial etiology and lack of response
to initial empiric antibiotic treatment in severe
CAP is not well established. How the relationship
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of the pulmonary parenchyma if the patient had
not been hospitalized or had resided in a long-
term care facility for * 14 days before the onset
of symptoms. All patients with severe CAP with-
out response to initial treatment were consecutive-
ly enrolled if they met the following criteria: re-
quiring mechanical ventilation after initial therapy;
more than two of the following presentations on
the day of enrollment: fever with temperature
> 38.5$C, abnormal white blood cell (WBC) count
(> 10,000 or < 4000/mm3), and purulent sputum;
bronchoalveolar lavage (BAL) study due to infil-
trates on chest radiograph. Patients were excluded
if they had received mechanical ventilation for
more than 3 days. Other exclusion criteria were
prednisolone > 20 mg/day, chemotherapy for can-
cer, HIV infection, lung cancer or other terminal-
stage malignancy. Consent for bronchoscopy study
in each case was obtained from either the patient
or the patient’s family. This study was approved
by the institutional review board of Taichung
Veterans General Hospital.
Data recorded for each patient included: age,
gender, date of onset of respiratory symptoms,
APACHE II score on the first ICU day, duration of
mechanical ventilation and Lung Injury Score12
on the day of BAL study. According to the period
from BAL study until the end of follow-up or death,
patients were divided into three groups: survivor
(survived for > 28 days after BAL); late mortality
(death at > 7 days but ) 28 days after BAL); rapidly
fatal (death ) 7 days after BAL).
Bronchoalveolar lavage
BAL study was performed as previously described.6
Briefly, BAL was guided by fiberoptic bronchosco-
py (Olympus BF 4B2, Olympus Optical Co Ltd,
Tokyo, Japan) with the patient under sedation.
The bronchoscope was introduced into the bron-
chus corresponding to the most abnormal area as
seen on the chest radiograph. In patients with dif-
fuse pulmonary infiltrates, the right middle lobe
or lingular segment was chosen. BAL was per-
formed by infusing six aliquots (20 mL each) of
sterile warm normal saline and retrieving immedi-
ately after each infusion. The first retrieved BAL
between mortality and immune response in
severe CAP varies according to bacterial etiology
also needs to be investigated. Monton et al stud-
ied lung and systemic inflammatory responses in
severe pneumonia, but found no clear relation-
ship between lung and systemic cytokine levels and
outcome, a finding which may be due to the small
sample size.2
Cytokines play an important role in inflamma-
tory lung disease. There is evidence that patients
with severe pneumonia who have persistent eleva-
tion of systemic cytokines have a higher risk of
mortality than controls.3–5 Tumor necrosis factor-
_ (TNF-_) and interleukin 1` (IL-1`) are early re-
sponse cytokines of pneumonia. IL-1` is also a
marker of bacterial burden in severe CAP.6 Inter-
leukin-8 (IL-8) is important for the recruitment
of inflammatory cells into the alveolar space,
which is related to the bacterial load in the alveo-
lar space.7 IL-10, an anti-inflammatory cytokine,
downregulates the expression of major histocom-
patibility complex class II molecules and attenu-
ates the release of proinflammatory cytokines. It
also has immunosuppressive properties.8,9 In sep-
tic patients, overproduction of IL-10 is a biomark-
er of severity and mortality.10 Glynn et al found
that circulating IL-10 was associated with signs
of systemic inflammatory response syndrome.11
However, there are limited data about the role
of bronchoalveolar and systemic IL-10 in severe
pneumonia.
This study investigated the bacterial etiology and
levels of proinflammatory and anti-inflammatory
cytokines in mechanically-ventilated patients with
severe CAP without response to initial empiric ther-
apy and their relation to mortality.
Methods
Patients
This study was conducted from July 1, 2000 to
October 31, 2001 in the respiratory intensive
care unit (RICU) of Taichung Veterans General
Hospital, a 1200-bed medical center in central
Taiwan. CAP was classified as an acute infection
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aliquot was discarded and the other BAL samples
were pooled for study. In addition, 5 mL of whole
blood was collected for determination of serum
cytokine levels.
Microbiologic specimen processing
After thorough mixing, 1 mL of BAL fluid was sent
to the laboratory for quantitative bacterial culture
within 30 minutes after collection. A 0.001-mL cal-
ibrated loop was placed in the BAL fluid and then
plated on tryptic soy agar (BD BioSciences, Taipei,
Taiwan), eosin methyl blue (BD BioSciences), choc-
olate agar (BD BioSciences) and Center for Dis-
ease Control anaerobic agar (BD BioSciences). All
of the cultures were incubated at 37$C under aer-
obic and anaerobic conditions. Bacterial growth
was evaluated 24 and 48 hours later. The bacterial
colonies were counted and definite pathogens were
defined as a bacterial count * 103 colony forming
units (cfu) per mL.13,14
BAL and serum cytokine assays
Whole blood and BAL fluid were centrifuged at
1500 rpm for 15 minutes and the serum and su-
pernatant were frozen at –70$C until further pro-
cessing. IL-1`, IL-8 and IL-10 levels were measured
in duplicate using commercial cytokine kits (Assay
Designs Inc, Ann Arbor, MI, USA) according to the
manufacturer’s protocol, as described in our pre-
vious study.6 Concentrations of plasma cytokines
were expressed as picograms per milliliter (pg/mL).
Statistical analysis
Values representing patient characteristics were ex-
pressed as mean ( standard deviation. The results
of BAL and serum cytokines were expressed as
mean ( standard error of the mean. Categorical
variables were analyzed by Pearson’s chi-square
test. The Kruskal-Wallis test was used for compari-
sons among the survivor, late mortality, and rap-
idly fatal groups. The Mann-Whitney U test was
used to compare continuous data between two
groups. Statistical analyses were performed using
SPSS version 8.0 (SPSS Inc, Chicago, IL, USA) for
Microsoft Windows. The significance was set at
_ = 0.05.
Results
Clinical characteristics
Forty-seven patients (42 male, 5 female) with a
mean age of 68 ( 17 years were enrolled. Most
patients had underlying diseases, including
cerebral vascular accident (n = 9), chronic obstruc-
tive pulmonary disease (n = 14), acute/chronic re-
nal failure (n = 12), or diabetes mellitus (n = 17).
The APACHE II score on the day of admission
was 23.4 ( 7.0. BAL study was performed 4.2 ( 3.3
days after the onset of respiratory symptoms,
and 1.7 ( 0.8 days after admission to our hospital.
The lung injury score at the time of BAL study was
2.3 ( 0.7. Because of failure of initial antibiotic
treatment, antibiotic regimens were changed
immediately after admission a mean of 1.4 ( 0.7
days prior to BAL study. The antibiotics included
in the last antibiotic regimens were (amoxicillin/
clavulanate or ampicillin/sulbactam) ( macrolide
(n = 14), penicillin ( macrolide (n = 18), cepha-
losporins (n = 5), piperacillin/tazobactam ( mac-
rolide (n = 5), and others (n = 5). Twenty-one died
within 28 days after admission. Compared with
survivors, patients who died had significantly
higher lung injury scores on the day of BAL study
(p = 0.039). Eight patients with a fulminant course
died within 7 days after BAL study. There were
26 patients in the survivor group, 13 in the late
mortality group, and eight in the rapidly fatal
group. The late mortality group and rapidly fatal
group had similar demographic characteristics
(Table 1).
Bacteriology of BAL study and cytokine
expression
Twenty-seven patients (57%) had positive quan-
titative bacterial culture (> 103 cfu/mL). Forty
microorganisms were isolated. Nine patients had
mixed infection with more than one organism. K.
pneumoniae and P. aeruginosa were the most com-
mon organisms isolated (Table 2). Acinetobacter
baumannii (n = 3) and Stenotrophomonas maltophilia
(n = 4) were also isolated in a few patients. A
pathogen was isolated in 87.5% of rapidly fatal
cases (7/8). K. pneumoniae was the most common
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etiology in rapidly fatal cases (5/8). Streptococcus
pneumoniae was not isolated in any of our pa-
tients. Ten patients had a K. pneumoniae infection
and four of them had mixed infection with P.
aeruginosa.
Further analysis was performed to compare cy-
tokine expression in patients with K. pneumoniae,
non-K. pneumoniae and unknown etiology. Patients
with a K. pneumoniae isolate had significantly
higher levels of BAL IL-1`, serum IL-8, and BAL
and serum IL-10 than patients with a non-K. pneu-
moniae isolate and patients with no pathogen iso-
lated (Table 3).
Expression of cytokines and patients’ outcome
Non-survivors had higher levels of serum IL-8
(p = 0.001), serum IL-10 (p < 0.001) and BAL
IL-10 (p = 0.039) than those who survived (Table
4). Neither serum nor BAL levels of IL-1` were
associated with outcome. Rapidly fatal cases were
characterized by a fulminant clinical course. As
shown in the Figure, there was an inverse relation-
ship between the expression of serum and BAL
cytokines and number of days before death. In
comparison to patients with late mortality, rapid-
ly fatal patients had elevated levels of BAL IL-1`,
serum IL-8, BAL IL-8, serum IL-10 and BAL IL-10.
Table 1. Demographic and clinical characteristics of patients according to outcome after
bronchoalveolar lavage (BAL)
Characteristic Survivor* (n = 26) Late mortality* (n = 13) Rapidly fatal* (n = 8)
Age (yr) 69 ( 18 67 ( 14 67 ( 20
Gender (M/F) 24/2 12/1 6/2
CVA (n) 5 1 3
Diabetes (n) 8 6 3
COPD (n) 100 3 1
Renal failure (n) 5 5 2
Lung injury score 02.1 ( 0.7† 2.5 ( 0.6 2.6 ( 0.6
APACHE II 22 ( 70 25 ( 80 25 ( 60
Onset to intubation‡ (d) 4.2 ( 3.3 4.7 ( 3.8 2.5 ( 1.9
Admission to BAL (d) 1.8 ( 0.8 1.5 ( 0.8 1.8 ( 0.9
Change of antibiotics to BAL (d) 1.6 ( 0.7 1.2 ( 0.7 1.2 ( 0.4
Culture positive rate§ (%) 50.0 53.8 87.5
*Survivor = alive for > 28 days after BAL, late mortality = death at > 7 days but ) 28 days after BAL, rapidly fatal = death ) 7
days after BAL; †p < 0.05 (Mann-Whitney U test); ‡onset to intubation = days from the onset of respiratory symptoms to acute respiratory
failure; §culture positive rate = bacteria * 103 cfu/mL. CVA = cerebral vascular accident; COPD = chronic obstructive pulmonary disease;
APACHE = acute physiology and chronic health evaluation.
Table 2. Isolates from bronchoalveolar lavage (BAL) (> 103 cfu/mL) in 27 patients with positive
bacterial culture
Isolate All patients Survivor* Late mortality* Rapidly fatal*
Pseudomonas aeruginosa 9 4 2 3
Acinetobacter baumannii 3 3 0 0
Staphylococcus aureus 4 4 0 0
Klebsiella pneumoniae 100 3 2 5
Escherichia coli 2 0 1 1
Stenotrophomonas maltophilia 4 1 2 1
Proteus mirabilis 1 1 0 0
Pseudomonas non-aeruginosa 3 0 1 2
Others 4 1 3 0
*Survivor = alive for > 28 days after BAL, late mortality = death at > 7 days but ) 28 days after BAL, rapidly fatal = death ) 7
days after BAL.
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However, only BAL IL-8 and BAL IL-10 were sig-
nificantly elevated.
Discussion
In this study of patients with severe CAP that
was nonresponsive to initial treatment and which
rapidly progressed to acute respiratory failure, K.
pneumoniae and P. aeruginosa were the most com-
mon pathogens isolated. Cytokine responses were
associated with the presence of K. pneumoniae. The
levels of serum IL-8, serum IL-10 and BAL IL-10
were higher in non-survivors. Cytokine expression
was markedly increased in rapidly fatal cases, but
only BAL IL-8 and BAL IL-10 were significantly
higher in the rapidly fatal group than in the late
mortality group (Figure). The finding that BAL IL-
10 levels were significantly associated with mor-
tality in patients with severe CAP has not been
previously reported.
In this study, patients had all been treated for
several days and their condition had deteriorated
to acute respiratory failure prior to transfer to the
RICU. Superimposed infection with P. aeruginosa,
A. baumannii and S. maltophilia may have been
caused by the previous use of antibiotics which
targeted S. pneumoniae. The clinical features of
patients with K. pneumoniae CAP are compatible
with previous reports on life-threatening pneumo-
nia due to K. pneumoniae in Taiwan.15,16
Expression of cytokines was markedly increased
in patients with a K. pneumoniae isolate compared
to those with other etiologies or no pathogen iso-
lated. The levels of BAL IL-1` were elevated both
in patients with K. pneumoniae and non-K. pneu-
moniae isolates, consistent with the finding of our
previous study that BAL IL-1` was a marker of
bacterial burden.6 The levels of BAL IL-1`, serum
IL-10 and BAL IL-10 were significantly higher
in patients with K. pneumoniae than in those with
other etiologies. A recent study showed that the
capsular polysaccharide synthesis regulators rmpA
and rmpA2 are virulence associated genes, and that
multiple iron-acquisition systems are also associ-
ated with virulence.17 These findings suggest that
K. pneumoniae could be more virulent than other
strains. The host immune response to K. pneumo-
niae requires further exploration.
Monton et al investigated the expression of
TNF-_, IL-1` and IL-6 in severe pneumonia,2 but
found no significant relationships between serum
and BAL cytokines and outcome. In this study, we
Table 3.  Serum and bronchoalveolar lavage (BAL) cytokine expression according to etiologies
Negative Only non-K. pneumoniae K. pneumoniae
Cytokine*  BAL culture isolated from BAL isolated from BAL p†
(n = 21) (n = 16) (n = 10)
Serum IL-1` 56.9 ( 7.40 50.7 ( 9.1 51.7 ( 8.800 0.699
BAL IL-1` 40.5 ( 10.3 150.0 ( 60.7 314.9 ( 113.4‡ 0.001
Serum IL-8 208.6 ( 53.80 169.3 ( 63.1 751.1 ( 109.2‡ 0.001
BAL IL-8 384.1 ( 80.80 .0564.8 ( 100.2 758.1 ( 111.60. 0.057
Serum IL-10 43.0 ( 10.4 046.5 ( 12.7 440.3 ( 122.1‡ 0.031
BAL IL-10 30.5 ( 23.1 06.3 ( 2.3 84.5 ( 43.3‡ 0.019
*Unit for cytokines is pg/mL (mean ( SEM); †Kruskal-Wallis test; ‡comparison between Non-K. pneumoniae and K. pneumoniae by
the Mann-Whitney U test and p < 0.05.
Table 4. Serum and bronchoalveolar lavage (BAL) cytokine
expression in survivors and non-survivors
Survivors Non-survivors
Cytokine*
(n = 26) (n = 21)
p†
Serum IL-1` 49.6 ( 6.5 58.4 ( 7.2 0.283
BAL IL-1` 111.2 ( 38.5 167.0 ( 61.8 0.906
Serum IL-8 141.5 ( 27.3 532.3 ( 93.6 0.001
BAL IL-8 0497.3 ( 565.0 565.0 ( 86.3 0.473
Serum IL-10 30.3 ( 6.1 260.4 ( 73.0 < 0.00100
BAL IL-10 021.8 ( 18.2 048.5 ( 22.2 0.039
*Unit for cytokines is pg/mL (mean ( SEM); †Mann-Whitney U test.
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also found that serum and BAL IL-1` was not
related to mortality. Although the level of BAL
IL-1` was higher in the rapidly fatal cases than the
other two subgroups, this difference was not sig-
nificant (p = 0.067). This finding is consistent with
the results of Rello et al’s study that mortality was
similar in patients with an etiologic diagnosis and
those with unknown etiology.18 In this study, both
serum and BAL IL-10 significantly predicted mor-
tality (Table 4). Higher levels of BAL and serum
IL-10 were associated with decreased survival
Figure. Serum and bronchoalveolar lavage (BAL) cytokines expressed as mean (
standard error. (A) Only serum IL-8 was significantly higher in fatal cases (Kruskal-
Wallis test, p < 0.05). (B) Both serum and BAL IL-10 were markedly increased in
rapidly fatal cases (Kruskal-Wallis test, p < 0.05). *p < 0.05 vs. survival; †p < 0.05 vs.
late mortality (Mann-Whitney U test).
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(Figure). Based on these findings, both local and
systemic IL-10 appear to be good markers for
predicting mortality in severe CAP with acute
respiratory failure without response to initial treat-
ment.
Glynn et al found that circulating IL-10 could
be detected in only 60% of simple CAP.11 They
concluded that IL-10 concentrations correlated
with severity of illness and may be of prognostic
importance. Gogos et al reported that in severe
sepsis, sustained overproduction of IL-10 was the
main predictor of severity and fatal outcome.10 Both
of these studies suggested that IL-10 was elevated
only in severe disease. The comparative severity of
our CAP patients, all of whom had acute respira-
tory failure with some in septic shock with multi-
ple organ failure, may explain the prognostic value
of serum and BAL IL-10 in this study.
This study had several limitations. First, cy-
tokine levels were not measured serially because
of the severity of illness. Therefore, the patterns
of cytokine expression could not be determined.
Second, we did not include a control group such
as patients with acute respiratory failure without
pneumonia. It is evident that cytokine expression
is lower in cardiogenic pulmonary edema than in
acute respiratory distress syndrome or pneumonia
patients.19 Third, all of our patients had changed
from previous antibiotics regimens to which they
had not responded to new regimens before the BAL
fluid study. Thus, the change in antibiotic therapy
may have affected the bacterial culture results and
cytokine expression. Finally, as informed consent
could not be obtained from every patient, a selec-
tion bias may have occurred.
The results of this study suggest that P. aerugi-
nosa and K. pneumoniae are the most important
causes of severe CAP necessitating mechanical
ventilation in Taiwan. K. pneumoniae induced a
marked immune response compared to other
etiologies. In addition, BAL and serum IL-10 were
markers of fatal outcome. Further study is needed
to determine if immunomodulatory therapy af-
fects cytokine profiles and clinical outcome in CAP
patients with acute respiratory failure that is not
responsive to initial treatment.
*†
*
*
†
*
*
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